The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
Dr Paul Anderson, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.
Dr Paul Anderson shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.
Dr David Borenstein, LDN Radio Show 28 Dec 2016 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.
Linda Elsegood: Today we are joined by Dr. David Bornstein. Thank you for joining us, David.
Dr David Borenstein: Thank you for having me.
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice
Gynecol Oncol
30 April 2011
https://pubmed.ncbi.nlm.nih.gov/21531450/
Low dose naltrexone: Harnessing the body's own chemistry to treat human ovarian cancer
Science Daily
13 July 2011
https://www.sciencedaily.com/releases/2011/07/110712143012.htm
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin
Exp Biol Med (Maywood)
July 2011
https://pubmed.ncbi.nlm.nih.gov/21685240/
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer
Exp Biol Med
May 2013
https://pubmed.ncbi.nlm.nih.gov/23856908/
Low-dose Naltrexone Targets the Opioid Growth Factor-Opioid Growth Factor Receptor Pathway to Inhibit Cell Proliferation: Mechanistic Evidence From a Tissue
Exp Biol Med (Maywood)
September 2011
https://pubmed.ncbi.nlm.nih.gov/21807817/